Project: Lactomezole, a safe and effective eradication therapy for H. Pylori without the use of antibiotics

Acronym	AVVALACT (Reference Number: 11089)
Duration	04/09/2017 - 04/09/2020
Project Topic	To develop a product, Lactomezole, as a new innovative standard of care for the management of dyspepsia and first line treatment for H. pylori infection, which is associated with dyspeptic and gastro-intestinal conditions, including gastric cancer. Lactomezole has significant OTC potential, as it will be the first proton pump inhibitor (PPI) plus prebiotic combo that has demonstrated eradication of H. pylori and normalization of GI tract microbiota without the use of antibiotics.
Network	Eurostars 2
Call	Eurostars Cut-Off 6

Project partner

Number	Name	Role	Country
1	AVVA Pharmaceuticals Ltd	Coordinator	Cyprus
2	ProtATonce Ltd	Partner	Greece
3	Cyprus University of Technology	Partner	Cyprus